PCSK9抑制剂对CHIP患者治疗策略转变的意义与展望  

The significance and prospect of PCSK9 inhibitors for the transformation of treatment strategies of CHIP patients

作　　者：周胜华[1] 陈鹏飞[1] ZHOU Shenghua;CHEN Pengfei(Department of Cardiology,Second Xiangya Hospital of Central South University,Changsha,410011,China)

机构地区：[1]中南大学湘雅二医院心血管内科,长沙410011

出　　处：《临床心血管病杂志》2022年第7期521-523,共3页Journal of Clinical Cardiology

摘　　要：高危复杂冠心病患者(CHIP)因冠脉病变解剖复杂或病情危重,传统药物治疗效果有限,往往需要高风险的复杂冠脉介入治疗。近年来,前蛋白转换酶枯草溶菌素9(PCSK9)抑制剂在冠心病的心血管不良事件获益上表现优异,对于CHIP这类特殊患者,PCSK9抑制剂的应用是否可减少支架植入,甚至对部分CHIP患者实现“药物血运重建”?乃至改变CHIP患者治疗策略选择,降低其需要高危介入治疗的风险,以及PCSK9抑制剂在CHIP患者的最佳应用时机,将是未来研究的热点。Complex high-risk indicated patients(CHIPs)often need high-risk and complex coronary interventional therapy due to the limited efficacy of traditional drug therapy.In recent years,PCSK9 inhibitors have performed well in the benefits of cardiovascular adverse events in coronary heart disease.Inthe future research,Theywill be the novel focus in CHIP patients,such aswhether the application of PCSK9 inhibitors can reduce stent implantation,and even achieve"drug revascularization",the changes of treatment strategies whichreduces the risk of high-risk interventional therapy,as well as the optimal time of PCSK9 inhibitors.

关 键 词：前蛋白转换酶枯草溶菌素9抑制剂 高危复杂冠心病 低密度脂蛋白胆固醇 心血管不良事件 

分 类 号：R541.4[医药卫生—心血管疾病]